Dayan, Steven H., et al. "A New Treatment Regimen for Rosacea: OnabotulinumtoxinA." Journal of Drugs in Dermatology : JDD, vol. 11, no. 12, 2012, pp. e76-9.
Dayan SH, Pritzker RN, Arkins JP. A new treatment regimen for rosacea: onabotulinumtoxinA. J Drugs Dermatol. 2012;11(12):e76-9.
Dayan, S. H., Pritzker, R. N., & Arkins, J. P. (2012). A new treatment regimen for rosacea: onabotulinumtoxinA. Journal of Drugs in Dermatology : JDD, 11(12), e76-9.
Dayan SH, Pritzker RN, Arkins JP. A New Treatment Regimen for Rosacea: OnabotulinumtoxinA. J Drugs Dermatol. 2012;11(12):e76-9. PubMed PMID: 23377526.
TY - JOUR
T1 - A new treatment regimen for rosacea: onabotulinumtoxinA.
AU - Dayan,Steven H,
AU - Pritzker,Rachel N,
AU - Arkins,John P,
PY - 2013/2/5/entrez
PY - 2013/2/5/pubmed
PY - 2013/8/14/medline
SP - e76
EP - 9
JF - Journal of drugs in dermatology : JDD
JO - J Drugs Dermatol
VL - 11
IS - 12
N2 - Rosacea is a cutaneous condition with several clinical subtypes that are commonly seen in daily medical practice. There are many different treatment modalities for each of the physical findings associated with this disease, and all have varying results. As the use of onabotulinumtoxinA rises, its benefit in the treatment of a growing number of medical diseases increases. The authors report anecdotal evidence of patients with rosacea experiencing improved symptoms of erythema and flushing after treatment with intradermal, microdroplets of onabotulinumtoxinA. There were no adverse events reported for any of the treatments. The mechanism of action through a likely neurogenic component to vascular dysfunction, inflammation, and hypersebaceous activity is reviewed.
SN - 1545-9616
UR - https://www.unboundmedicine.com/medline/citation/23377526/A_new_treatment_regimen_for_rosacea:_onabotulinumtoxinA_
L2 - http://jddonline.com/articles/dermatology/S1545961612E0076X
DB - PRIME
DP - Unbound Medicine